Unlocking the Power of Decentralized Drug Distribution: How DDD Can Work for Tuberculosis, Noncommunicable Diseases and Family Planning
- Shared screen with speaker view

16:55
HI

17:48
Sarah and Moses, please let me know when it is ok to start

17:58
Welcome and thank you for joining us. Feel free to introduce yourself in the chat.

18:09
Go ahead Paul

18:12
Edward OladeleFHI 360.

18:15
Hi, This is Bhagawan from EpiC Nepal

18:18
Hello Cathy Michel EpiC MZ

18:26
Greetings everyone

18:37
I am Gashubije Longin from Burundi

18:51
Edward Oladele, FHI 360>Greetings everyone

18:51
Patrick Makelele -FHI360 Zambia Technical Advisor

19:09
HI there from MJ Schoemaker at ARC! Thanks for organising this event!!

19:58
Makoae Mosothoane, Right to Care Lesotho. Greetings everyons

20:17
Tari Mavimba, ZHI (FHI360 sub, Zimbabwe)

21:00
Francine Karemera, FHI 360 Burundi

24:48
Dr Advocate Nkhosikhona Dlamini, ENAP/MOH,Kingdom of eSwatini

25:11
Esinath Derera FHI360 Mhuri/imuli Hello everyone

25:49
Maggie Munsamy: NHI: Technical Specialist , HEAD: CCMDD, Ministry of Health, South Africa

25:50
Good morning/afternoon, Dennis Osiemo USAID KEA

26:45
Dorothy Oqua, Howard University Global Initiative Nigeria

27:37
Anthony Okoth, ARC Kenya

27:46
Pugie Chimberengwa; Technical Director-OPHID, Zimbabwe

28:46
Onwubiko Samuel, Senior Technical Officer, Achieving Health Nigeria Initiative, Nigeria.

29:10
Nyaradzo Muhonde, FHI360, Technical Director Mhuri/Imuli

29:23
Phil Roberts ,Project Last Mile South Africa

32:12
Tari Mavimba, ZHI (FHI360 sub, Zimbabwe)

33:18
Phil Roberts ,Project Last Mile South Africa

34:28
Ezenduka Johnbaptist (AHNi, Nigeria)

34:30
Warm greetings to you all, Khesiwe Ncube , FHI360 -Mhuri/Imuli Project , Zimbabwe

37:14
Mazwi Dzapasi ,Africa Resource Centre, South Africa

39:14
Morgen Muzondo, ZHI (FHI360 sub, Zimbabwe)

42:09
Morgen Muzondo, ZHI (FHI360 sub, Zimbabwe)

42:21
Moses Bateganya, FHI 360/EpiC

42:38
Ashley Greve, USAID/OHA

43:35
Nsoh Marius, Fhi360/ EpiC Cameroon.

43:50
Frederick Mubiru FHI 360/ R4S

44:15
Robert Makombe, FHI 360/EpiC

45:00
Tendai Samushonga, ZHI (FHI360 sub, Zimbabwe)

45:52
Afusat Adesina,Howard UniversitySHARP TO2 project,,Nigeria

51:00
Bronwyn Timm, Africa Resource Centre

52:13
Andrew Maranga, EpiC Mozambique

01:00:35
James Batuka

01:01:10
There are some questions in the chat and in the Q&A

01:18:01
when sharing in the chat please send to all not just panelists.

01:24:54
ALL: I haven't seen any response to Dr Tran's question on how TB dispensing is happening in the countries participating on the call? If you have any practical experiences please share

01:28:16
Yes, please share! You are doing great work and we want to learn from you!

01:30:47
I’m not sure the audience members have speaking permissions

01:31:23
Sara h are people able to unmute?

01:32:17
No but I unmuted Dr. Unamba but they haven't spoken

01:32:50
Fred only had two slides left so let's use the rest of the time for Q+A

01:34:21
Fred it back so let's engage him in the Q+A please

01:36:33
Sorry I have to participate in another meeting. Congratulation to the team I wish the community distribution will solve the issue of workload and improuve access without harming the users.

01:38:16
Fred, based on your experience do you think drug shops can distribute ART safely? if so what would we need to do to use them?

01:39:50
Hello team,I wanted to ask the following question. I wanted to find out if we needed to have policy change and come up with another policy framework at national level. Before DSD being scaled up we had to go through these processes at national level . Do we need to do the same to include other product different from ARVs we advocated DSD for?

01:40:13
In Edwatini: Drug sensitive TB Medicine is dispensed in the similar manner as the HIV Medicine. It is coordinated by nurses from the same facilities as they go to outreach. Not that in Eswatini majority of TB patients are co-infected with HIV

01:40:48
...NOTE THAT...

01:40:50
Hi Patrick -great question. In many countries, there are already supportive policies for integration. So first it would be to check the policies around integration and see if it’s a policy barrier, or a challenge with implementation.

01:41:46
I might have missed, using the community approach of DDD, how do you maintain privacy and confidentiality issues at PUP

01:41:59
Hi Jane, thanks for your question on DMPA-SC, the unit does not need any refrigeration and should be stable even in hot climates. For expiration dates, those providing the units will monitor for expiration prior to dispensing.

01:42:48
Please share how you follow side effects of the injections

01:43:41
for DMPA-SC injection 3 months supply. How does one identify the expiry date of a product at home as the individual uniject do not have the expiry date printed on them. Are there additional labelling of the 3 moth MDD? How is the storage conditions maintained in very hot and humid areas e.g. Soroti (Uganda), when one does not have a refrigerator? This might affect the efficacy of the drug

01:44:21
For DMPA-SC side effects, patients should be counseled before using the method on what to expect for side effects, mainly some bleeding can occur. Those providing should counsel so women know to expect this. Side effect information is also covered in job aids and videos easily accessible by clients.

01:44:28
To register for our next session please click here: https://bit.ly/3p6311f

01:45:04
Thanks to all speakers and great job!

01:45:09
Thanks all - have another call now so will sign off. Hope we can all share slides and get emails of the panellists to talk more. Have a good week!